HD-OPM Archive
Hashtags

#pav

15 posts

Colchicine 0.5 mg cut plaque volume by over 1% in one year on CT angiography (Budoff)

May 11, 2025 · Louis Nervegna ♥ 20 · 💬 37 ↩ 9 Plaque, CAC & CT angiography

Louis highlights a Budoff-led CCTA trial in which low-dose colchicine reduced percent atheroma volume by over 1% in a year, with lower CRP and a slowing of calcified plaque. He contrasts this with the Keto-CTA study, where PAV rose 0.8% on a keto diet. Budoff notes it was a small study but supports colchicine in chronic stable coronary disease.

Statin plaque regression RCTs: SATURN, REVERSAL, ASTEROID, COSMOS, JAPAN-ACS

Jan 18, 2025 · Louis Nervegna ♥ 10 · 💬 29 ↩ 9 Plaque, CAC & CT angiography

Louis lists human trials in which statins reversed or halted atheroma growth measured as percent atheroma volume (PAV). High-dose atorvastatin and rosuvastatin regressed PAV in SATURN and ASTEROID, while REVERSAL showed halted progression versus pravastatin. COSMOS added canakinumab to rosuvastatin, and PROSPECT and JAPAN-ACS showed lower progression on statins.

Six RCTs show statins reverse total plaque volume by 5% to 17%

Aug 25, 2026 · Louis Nervegna ♥ 27 · 💬 9 ↩ 1 Plaque, CAC & CT angiography

Louis lists six randomized trials showing reversal of total atheroma volume with statins: COSMOS ~5%, SATURN ~5.5%, ASTEROID ~6.5%, IBIS-4 ~7.5%, STABLE ~8%, JAPAN-ACS ~17%. Reversals were measured by CT angiography or IVUS and came from soft rather than calcified plaque. A shared chart relates LDL to TAV change across statin, PCSK9 and ezetimibe trials.

Keto-CTA: LMHR group's 0.8% plaque volume rise exceeded that of typical Western cohorts

Apr 08, 2025 · Louis Nervegna ♥ 18 · 💬 14 Plaque, CAC & CT angiography

Louis expresses disappointment in the LMHR prospective cohort study, in which lean, metabolically healthy keto dieters with very high LDL had total plaque volume rise 0.8% in a year. He cites the paper's supplemental table, which he says shows other Western cohorts progressing less, and notes that no participant showed NCPV regression and that those with the most baseline plaque progressed the most.

Keto-CTA (LMHR): plaque volume rose 25-100% in one year across CAC and risk subgroups

Apr 09, 2025 · Louis Nervegna ♥ 10 · 💬 6 ↩ 2 Plaque, CAC & CT angiography

Louis walks through a table from the Keto-CTA (LMHR) paper showing percent atheroma volume (PAV) changes after one year in lean, metabolically healthy people on keto with average LDL 254 mg/dL. Plaque progressed in every subgroup, with the largest relative increase among those who started with zero CAC. He also explains what PAV measures.

Six statin trials show 5 to 17% total plaque reversal, with the best results at lowest LDL

Oct 31, 2026 · Louis Nervegna ♥ 12 ↩ 1 Plaque, CAC & CT angiography

Louis shares a chart of randomized trials showing plaque reversal with statins, ezetimibe and PCSK9 inhibitors, with total atheroma volume change plotted against LDL-C. Total plaque reversal ranged from about 5% to 17% in six older statin trials, measured by CT angiography or IVUS, and came from soft rather than calcified plaque. The chart suggests total plaque reversal begins once LDL falls below roughly 90 mg/dL.

Letter to JACC: Keto-CTA omitted pre-specified outcome, a 43% rise in non-calcified plaque

Apr 21, 2025 · Louis Nervegna ♥ 4 · 💬 1 Plaque, CAC & CT angiography

Louis shares a letter to the editor critiquing the Keto-CTA study of lean mass hyper-responders. It argues the primary outcome (non-calcified plaque volume) was not reported in the paper, but the lead author later shared a median increase of 18.8 mm3 (~43%), several-fold above normal annual progression and in contrast to regression seen in DISCO-CT. The 0.8% rise in percent atheroma volume also exceeds typical annual change in PARADIGM.